Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Clin Cancer Res. 2013 Dec 1;19(23):10.1158/1078-0432.CCR-13-0734. doi: 10.1158/1078-0432.CCR-13-0734

Figure 3. An approach to immune eradication of residual micrometastases in breast cancer.

Figure 3

(A) Based on prognostic signatures, consideration must be given to both controlling breast cancer growth as well as increasing Type 1 T-cells in the tumor environment. (B) Based on the initial immune score at the time of diagnosis multi-modality treatment approaches with concurrent and/or sequential strategies may be able to achieve the optimal immune score in all breast cancer patients rather than in just a minority.